ICON Public (NASDAQ:ICLR) Price Target Raised to $349.00 at TD Cowen

ICON Public (NASDAQ:ICLR - Get Free Report) had its target price increased by equities research analysts at TD Cowen from $343.00 to $349.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a "buy" rating on the medical research company's stock. TD Cowen's price objective would indicate a potential upside of 13.20% from the company's current price.

Several other brokerages have also recently issued reports on ICLR. Evercore ISI boosted their price target on ICON Public from $325.00 to $350.00 and gave the company an "outperform" rating in a research report on Friday, February 23rd. Truist Financial boosted their price target on ICON Public from $357.00 to $367.00 and gave the company a "buy" rating in a research report on Friday, February 23rd. Barclays boosted their price target on ICON Public from $325.00 to $355.00 and gave the company an "overweight" rating in a research report on Friday, February 23rd. Mizuho reaffirmed a "buy" rating and issued a $346.00 price objective on shares of ICON Public in a report on Thursday, April 4th. Finally, Robert W. Baird lifted their price objective on ICON Public from $362.00 to $363.00 and gave the company an "outperform" rating in a report on Friday. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $321.64.

ICON Public Stock Performance

Shares of ICLR traded up $8.23 during midday trading on Friday, reaching $308.31. 715,419 shares of the stock were exchanged, compared to its average volume of 566,547. The business's 50-day moving average price is $318.89 and its 200 day moving average price is $282.81. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.21 and a quick ratio of 1.21. ICON Public has a twelve month low of $181.92 and a twelve month high of $344.77. The company has a market capitalization of $25.44 billion, a price-to-earnings ratio of 37.51, a PEG ratio of 1.46 and a beta of 1.15.

ICON Public (NASDAQ:ICLR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.27 by $0.13. The firm had revenue of $2.07 billion for the quarter, compared to analysts' expectations of $2.08 billion. ICON Public had a return on equity of 11.84% and a net margin of 8.30%. On average, sell-side analysts expect that ICON Public will post 14.4 EPS for the current fiscal year.

Institutional Investors Weigh In On ICON Public

Several institutional investors have recently modified their holdings of the company. Riverview Trust Co purchased a new stake in shares of ICON Public during the 1st quarter worth approximately $31,000. Steph & Co. raised its position in shares of ICON Public by 11.2% during the 1st quarter. Steph & Co. now owns 1,852 shares of the medical research company's stock worth $622,000 after purchasing an additional 186 shares during the last quarter. GAMMA Investing LLC grew its holdings in ICON Public by 22.5% during the 1st quarter. GAMMA Investing LLC now owns 174 shares of the medical research company's stock valued at $58,000 after buying an additional 32 shares during the last quarter. Livelsberger Financial Advisory acquired a new stake in ICON Public during the 4th quarter valued at $29,000. Finally, State of Tennessee Treasury Department grew its holdings in ICON Public by 4.9% during the 4th quarter. State of Tennessee Treasury Department now owns 155,797 shares of the medical research company's stock valued at $44,101,000 after buying an additional 7,270 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company's stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.